<?xml version="1.0" encoding="UTF-8"?>
<p>Brazil was able to obtain an unprecedented discount for an upper‐middle‐income country through price negotiations with originator pharmaceutical companies. Between 2015 and 2018 it provided treatment to nearly 90 000 people, and is expected to treat another 50 000 patients in 2019, largely thanks to the strong advocacy of civil society.</p>
